Autopsy report · NCT03597282
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
Cause of deathSlow enrollment, also staffing, sites or logistics
“Closed due to historically slow enrollment compounded by the COVID-19 pandemic.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 1 year 10 months before it stopped.
- 22 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- BioNTech US Inc.
- Sponsor type
- Industry
- Conditions
- Metastatic Melanoma
- Interventions
- NEO-PV-01; Nivolumab; Adjuvant; APX005M; ipilimumab
- Participants
- 22
- Sites
- 8
- Countries
- United States
Trials that died the same way
- Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia
“temporarily closed to enrollment due to COVID” - A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
“Closed due to slow enrollment” - Effects of rTMS on Human Brain Activity
“Never started enrollment due to COVID-19 closures” - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
“Enrollment halted prematurely due to the Covid-19 pandemic” - Intranasal Insulin for the Treatment of HAND
“On 3/15/2020 study visits were suspended due to COVID-19 pandemic. With safety concerns surrounding COVID-19 and difficulty recruiting, the investigators decided to close enrollment 10/16/2020 after interim data were reviewed by the DSMB and NIH.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.